Medical Device Reporting; Malfunction Reporting Frequency, 12743-12744 [2011-5146]

Download as PDF Federal Register / Vol. 76, No. 45 / Tuesday, March 8, 2011 / Notices device, including, but not limited to, implanted electrical urinary continence devices; implanted mechanical/ hydraulic urinary continence devices; urological clamp for males; nonimplanted, peripheral and other electrical continence devices; protective garment for incontinence; surgical mesh; electrosurgical cutting and coagulation device and accessories; perineometer; gynecologic laparoscope and accessories; and vaginal pessary. In the Federal Register of September 19, 2008 (73 FR 54406), FDA announced the availability of the draft guidance. Comments on the draft guidance were due by December 18, 2008. Two comments were received with each comment making multiple recommendations on changes to the content of the guidance document. The comments included recommended changes to or removals of primary, secondary, and composite endpoints and changes to the recommended clinical study design. In response to these comments, FDA has clarified the appropriate context for recommended endpoints and a sponsor’s options with respect to use of a given endpoint. FDA also revised the recommended requirements for use of voiding diaries and clarified the recommendation regarding the randomization of subjects. Comments also involved recommendations on the categorization of adverse events. In response to these comments, FDA clarified the recommendation for categorization of adverse events as either device- or procedure-related. srobinson on DSKHWCL6B1PROD with NOTICES II. Significance of Guidance This guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The guidance represents the Agency’s current thinking on clinical investigations of devices intended to treat urinary incontinence. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute and regulations. III. Electronic Access Persons interested in obtaining a copy of the guidance may do so by using the Internet. A search capability for all CDRH guidance documents is available at https://www.fda.gov/MedicalDevices/ DeviceRegulationandGuidance/ GuidanceDocuments/default.htm. Guidance documents are also available at https://www.regulations.gov. To receive ‘‘Clinical Investigations of VerDate Mar<15>2010 19:12 Mar 07, 2011 Jkt 223001 Devices Indicated for the Treatment of Urinary Incontinence,’’ you may either send an e-mail request to dsmica@fda.hhs.gov to receive an electronic copy of the document or send a fax request to 301–847–8149 to receive a hard copy. Please use the document number 1636 to identify the guidance you are requesting. IV. Paperwork Reduction Act of 1995 This guidance refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501– 3520). The collections of information in 21 CFR part 812 have been approved under OMB control number 0910–0078; the collections of information in 21 CFR part 807, subpart E, have been approved under OMB control number 0910–0120; the collections of information in 21 CFR part 814 have been approved under OMB control number 0910–0231; and the collections of information in 21 CFR parts 50.23 and 56.115 have been approved under OMB control number 0910–0130. V. Comments Interested persons may submit to the Division of Dockets Management (see ADDRESSES), either electronic or written comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Dated: March 2, 2011. Leslie Kux, Acting Assistant Commissioner for Policy. [FR Doc. 2011–5148 Filed 3–7–11; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2011–N–0097] Medical Device Reporting; Malfunction Reporting Frequency AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is clarifying that device manufacturers and importers of SUMMARY: PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 12743 all devices, including class I and those class II devices that are not permanently implantable, life supporting, or life sustaining, must continue to submit malfunction reports in full compliance with FDA’s Medical Device Reporting regulation, pending future FDA notice under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). DATES: Submit either electronic or written comments by May 9, 2011. ADDRESSES: Submit electronic comments on this document to https:// www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Identify comments with the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Victoria Schmid, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 3236, Silver Spring, MD 20993–0002, 301–796–6108. I. Background Title II, section 227 of the Food and Drug Administration Amendments Act of 2007 (FDAAA) (Public Law 110–85), amended section 519(a) of the FD&C Act (21 U.S.C. 360i(a)), relating to the reporting of malfunctions to FDA under part 803 (21 CFR part 803). The malfunction reporting requirements for class III devices and those class II devices that are permanently implantable, life supporting, or life sustaining were not altered by FDAAA. Under the amended section 519(a), device manufacturers and importers are to continue to submit malfunction reports in accordance with part 803 for all class III devices and for those class II devices that are permanently implantable, life supporting, or life sustaining, unless the Secretary of Health and Human Services (the Secretary) (and, by delegation, FDA) grants an exemption, variance from, or an alternative to, a requirement under such regulations under § 803.19 (section 519(a)(1)(B)(i) of the FD&C Act). However, FDAAA changed malfunction reporting requirements for class I devices and those class II devices that are not permanently implantable, life supporting, or life sustaining. Under section 519(a) of the FD&C Act, as amended by FDAAA, the Secretary (and, by delegation, FDA) is required to publish a notice in the Federal Register or send a letter to the person who is the manufacturer or importer of a class I device or a class II device that is not permanently implantable, life E:\FR\FM\08MRN1.SGM 08MRN1 12744 Federal Register / Vol. 76, No. 45 / Tuesday, March 8, 2011 / Notices srobinson on DSKHWCL6B1PROD with NOTICES supporting, or life sustaining, if FDA finds that such a device should be subject to part 803 in order to protect the public health (section 519(a)(1)(B)(i)(III) of the FD&C Act). If such class I or class II devices are not the subject of an FDA notice or letter, the malfunction reports for these devices are to be submitted in accordance with the criteria established by the Secretary (and, by delegation, FDA), which criteria shall require the reports to be in summary form and made on a quarterly basis (section 519(a)(1)(B)(ii) of the FD&C Act). Under section 519(a) of the FD&C Act, as amended by FDAAA, there is no change to the obligation for an importer to submit malfunction reports to the manufacturer in accordance with part 803 for devices that it imports into the United States (section 519(a)(1)(B)(iii) of the FD&C Act). FDA intends to provide notice in the Federal Register that lists the types of devices that should be subject to part 803 in order to protect the public health, as required by section 519(a)(1)(B)(i)(III) of the FD&C Act). In addition, FDA intends to, by rulemaking, establish malfunction reporting criteria for devices subject to section 519(a)(1)(B)(ii) of the FD&C Act. In the interim, in the interest of public health, FDA is publishing this notice under section 519(a)(1)(B)(i)(III), to clarify that, to the extent there is any confusion as to current malfunction reporting requirements, all device manufacturers and importers of class I and those class II devices that are not permanently implantable, life supporting, or life sustaining, must continue to report in full compliance with part 803, pending further FDA notice under section 519(a)(1)(B)(i)(III), as to specific devices or device types subject to part 803, and the establishment of criteria in accordance with section 519(a)(1)(B)(ii). FDA considers it necessary to subject all such devices to part 803 in the interim, in order to protect the public health by ensuring that there is no gap in malfunction reporting for any device. II. Comments Interested persons may submit to the Division of Dockets Management (see ADDRESSES) either electronic or written comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. VerDate Mar<15>2010 19:12 Mar 07, 2011 Jkt 223001 [FR Doc. 2011–5146 Filed 3–7–11; 8:45 am] Dated: March 2, 2011. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. BILLING CODE 4160–01–P [FR Doc. 2011–5228 Filed 3–7–11; 8:45 am] Dated: March 2, 2011. Leslie Kux, Acting Assistant Commissioner for Policy. BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute On Deafness and Other Communication Disorders; Notice of Closed Meetings National Center for Complementary & Alternative Medicine; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; Clinical Trials—Communications. Date: March 31, 2011. Time: 12 p.m. to 2 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6120 Executive Blvd., Rockville, MD 20852. (Telephone Conference Call.) Contact Person: Christine A. Livingston, PhD, Scientific Review Officer, Division of Extramural Activities, National Institutes of Health/NIDCD, 6120 Executive Blvd.—MSC 7180, Bethesda, MD 20892, (301) 496–8683, livingsc@mail.nih.gov. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; P50 Grant Review. Date: April 8, 2011. Time: 11 a.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6120 Executive Blvd., Rockville, MD 20852. (Telephone Conference Call.) Contact Person: Christine A. Livingston, PhD, Scientific Review Officer, Division of Extramural Activities, National Institutes of Health/NIDCD, 6120 Executive Blvd.—MSC 7180, Bethesda, MD 20892, (301) 496–8683, livingsc@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.173, Biological Research Related to Deafness and Communicative Disorders, National Institutes of Health, HHS) Name of Committee: National Center for Complementary and Alternative Medicine Special Emphasis Panel, NCCAM Education Panel. Date: March 24–25, 2011. Time: 12 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy Chase, MD 20815. Contact Person: Peter Kozel, PhD., Scientific Review Officer, NCCAM, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892–5475, 301–496–8004, kozelp@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS) PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 Dated: March 2, 2011. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2011–5226 Filed 3–7–11; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as E:\FR\FM\08MRN1.SGM 08MRN1

Agencies

[Federal Register Volume 76, Number 45 (Tuesday, March 8, 2011)]
[Notices]
[Pages 12743-12744]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-5146]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0097]


Medical Device Reporting; Malfunction Reporting Frequency

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is clarifying that 
device manufacturers and importers of all devices, including class I 
and those class II devices that are not permanently implantable, life 
supporting, or life sustaining, must continue to submit malfunction 
reports in full compliance with FDA's Medical Device Reporting 
regulation, pending future FDA notice under the Federal Food, Drug, and 
Cosmetic Act (the FD&C Act).

DATES: Submit either electronic or written comments by May 9, 2011.

ADDRESSES: Submit electronic comments on this document to https://www.regulations.gov. Submit written comments to the Division of Dockets 
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, 
rm. 1061, Rockville, MD 20852. Identify comments with the docket number 
found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Victoria Schmid, Center for Devices 
and Radiological Health, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 66, rm. 3236, Silver Spring, MD 20993-0002, 301-
796-6108.

I. Background

    Title II, section 227 of the Food and Drug Administration 
Amendments Act of 2007 (FDAAA) (Public Law 110-85), amended section 
519(a) of the FD&C Act (21 U.S.C. 360i(a)), relating to the reporting 
of malfunctions to FDA under part 803 (21 CFR part 803). The 
malfunction reporting requirements for class III devices and those 
class II devices that are permanently implantable, life supporting, or 
life sustaining were not altered by FDAAA. Under the amended section 
519(a), device manufacturers and importers are to continue to submit 
malfunction reports in accordance with part 803 for all class III 
devices and for those class II devices that are permanently 
implantable, life supporting, or life sustaining, unless the Secretary 
of Health and Human Services (the Secretary) (and, by delegation, FDA) 
grants an exemption, variance from, or an alternative to, a requirement 
under such regulations under Sec.  803.19 (section 519(a)(1)(B)(i) of 
the FD&C Act).
    However, FDAAA changed malfunction reporting requirements for class 
I devices and those class II devices that are not permanently 
implantable, life supporting, or life sustaining. Under section 519(a) 
of the FD&C Act, as amended by FDAAA, the Secretary (and, by 
delegation, FDA) is required to publish a notice in the Federal 
Register or send a letter to the person who is the manufacturer or 
importer of a class I device or a class II device that is not 
permanently implantable, life

[[Page 12744]]

supporting, or life sustaining, if FDA finds that such a device should 
be subject to part 803 in order to protect the public health (section 
519(a)(1)(B)(i)(III) of the FD&C Act). If such class I or class II 
devices are not the subject of an FDA notice or letter, the malfunction 
reports for these devices are to be submitted in accordance with the 
criteria established by the Secretary (and, by delegation, FDA), which 
criteria shall require the reports to be in summary form and made on a 
quarterly basis (section 519(a)(1)(B)(ii) of the FD&C Act).
    Under section 519(a) of the FD&C Act, as amended by FDAAA, there is 
no change to the obligation for an importer to submit malfunction 
reports to the manufacturer in accordance with part 803 for devices 
that it imports into the United States (section 519(a)(1)(B)(iii) of 
the FD&C Act).
    FDA intends to provide notice in the Federal Register that lists 
the types of devices that should be subject to part 803 in order to 
protect the public health, as required by section 519(a)(1)(B)(i)(III) 
of the FD&C Act). In addition, FDA intends to, by rulemaking, establish 
malfunction reporting criteria for devices subject to section 
519(a)(1)(B)(ii) of the FD&C Act. In the interim, in the interest of 
public health, FDA is publishing this notice under section 
519(a)(1)(B)(i)(III), to clarify that, to the extent there is any 
confusion as to current malfunction reporting requirements, all device 
manufacturers and importers of class I and those class II devices that 
are not permanently implantable, life supporting, or life sustaining, 
must continue to report in full compliance with part 803, pending 
further FDA notice under section 519(a)(1)(B)(i)(III), as to specific 
devices or device types subject to part 803, and the establishment of 
criteria in accordance with section 519(a)(1)(B)(ii). FDA considers it 
necessary to subject all such devices to part 803 in the interim, in 
order to protect the public health by ensuring that there is no gap in 
malfunction reporting for any device.

II. Comments

    Interested persons may submit to the Division of Dockets Management 
(see ADDRESSES) either electronic or written comments regarding this 
document. It is only necessary to send one set of comments. It is no 
longer necessary to send two copies of mailed comments. Identify 
comments with the docket number found in brackets in the heading of 
this document. Received comments may be seen in the Division of Dockets 
Management between 9 a.m. and 4 p.m., Monday through Friday.

    Dated: March 2, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-5146 Filed 3-7-11; 8:45 am]
BILLING CODE 4160-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.